Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Orell Mielke

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Radiology|April 29, 2005
Early signs of brain infarction at CT: observer reliability and outcome after thrombolytic treatment--systematic reviewJoanna M Wardlaw, Orell Mielke
Immunotherapy|May 17, 2018
IgPro20, the Polyneuropathy and Treatment with Hizentra<sup>®</sup> study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgGMelvin Berger, Thomas Harbo, David R Cornblath, et al.
Stroke|October 16, 2004
Transient ischemic attacks are more than "ministrokes"Michael Daffertshofer, Orell Mielke, Arne Pullwitt, et al.
Cerebrovascular Diseases (Basel, Switzerland)|June 26, 2004
Early motor evoked potentials in acute stroke: adjunctive measure to MRI for assessment of prognosis in acute stroke within 6 hoursJohannes C Wöhrle, Stephan Behrens, Orell Mielke, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|October 11, 2020
Electrophysiological testing in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin: The Polyneuropathy And Treatment with Hizentra (PATH) studyVera Bril, Hans-Peter Hartung, John-Philip Lawo, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|July 22, 2021
Electrophysiological predictors of response to subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathyMonica Alcantara, Hans-Peter Hartung, John-Philip Lawo, et al.
Transfusion|August 2, 2022
Incidence and risk factors for intravenous immunoglobulin-related hemolysis: A systematic review of clinical trial and real-world populationsHillary Cuesta, Ibrahim El Menyawi, Alphonse Hubsch, et al.
Stroke|March 10, 2007
Factors influencing the detection of early CT signs of cerebral ischemia: an internet-based, international multiobserver studyJoanna M Wardlaw, Andrew J Farrall, David Perry, et al.
Transfusion|August 26, 2017
Hemolysis related to intravenous immunoglobulins is dependent on the presence of anti-blood group A and B antibodies and individual susceptibilityOrell Mielke, Stefano Fontana, Vesselina Goranova-Marinova, et al.
Journal of the Peripheral Nervous System : JPNS|March 10, 2022
Analysis of relapse by inflammatory Rasch-built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathyIngemar S J Merkies, Ivo N van Schaik, Vera Bril, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Radiology|April 29, 2005
Early signs of brain infarction at CT: observer reliability and outcome after thrombolytic treatment--systematic reviewJoanna M Wardlaw, Orell Mielke
Immunotherapy|May 17, 2018
IgPro20, the Polyneuropathy and Treatment with Hizentra<sup>®</sup> study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgGMelvin Berger, Thomas Harbo, David R Cornblath, et al.
Stroke|October 16, 2004
Transient ischemic attacks are more than "ministrokes"Michael Daffertshofer, Orell Mielke, Arne Pullwitt, et al.
Cerebrovascular Diseases (Basel, Switzerland)|June 26, 2004
Early motor evoked potentials in acute stroke: adjunctive measure to MRI for assessment of prognosis in acute stroke within 6 hoursJohannes C Wöhrle, Stephan Behrens, Orell Mielke, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|October 11, 2020
Electrophysiological testing in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin: The Polyneuropathy And Treatment with Hizentra (PATH) studyVera Bril, Hans-Peter Hartung, John-Philip Lawo, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|July 22, 2021
Electrophysiological predictors of response to subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathyMonica Alcantara, Hans-Peter Hartung, John-Philip Lawo, et al.
Transfusion|August 2, 2022
Incidence and risk factors for intravenous immunoglobulin-related hemolysis: A systematic review of clinical trial and real-world populationsHillary Cuesta, Ibrahim El Menyawi, Alphonse Hubsch, et al.
Stroke|March 10, 2007
Factors influencing the detection of early CT signs of cerebral ischemia: an internet-based, international multiobserver studyJoanna M Wardlaw, Andrew J Farrall, David Perry, et al.
Transfusion|August 26, 2017
Hemolysis related to intravenous immunoglobulins is dependent on the presence of anti-blood group A and B antibodies and individual susceptibilityOrell Mielke, Stefano Fontana, Vesselina Goranova-Marinova, et al.
Journal of the Peripheral Nervous System : JPNS|March 10, 2022
Analysis of relapse by inflammatory Rasch-built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathyIngemar S J Merkies, Ivo N van Schaik, Vera Bril, et al.
Pageof 2